Search research articles
Contact Us
Filters
Showing results (21-30 of 54) with videos related to
Page
of 6
Sort By:
Developmental Biology
|
November 1, 1977
Human teratoma cells share antigens with mouse teratoma cells
S Ostrand-Rosenberg, M Edidin, M A Jewett
Journal of Immunology (Baltimore, Md. : 1950)
|
November 9, 2000
Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo
L Qi, J M Rojas, S Ostrand-Rosenberg
Journal of Immunology (Baltimore, Md. : 1950)
|
December 1, 1993
Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection
E Lamousé-Smith, V K Clements, S Ostrand-Rosenberg
Journal of Immunology (Baltimore, Md. : 1950)
|
June 1, 1983
Multiple splenic lymphoid cell subpopulations regulate H-2 antigen expression on teratocarcinoma cells in vivo
S Ostrand-Rosenberg, A L Cohn, J W Sandoz
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 4, 1998
Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo
T D Armstrong, V K Clements, S Ostrand-Rosenberg
Journal of Immunology (Baltimore, Md. : 1950)
|
April 29, 1998
MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes
T D Armstrong, V K Clements, S Ostrand-Rosenberg
Cancer Immunology, Immunotherapy : CII
|
April 29, 1998
Tumor antigen presentation: changing the rules
T D Armstrong, B A Pulaski, S Ostrand-Rosenberg
Journal of Immunology (Baltimore, Md. : 1950)
|
November 22, 2000
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
S Ostrand-Rosenberg, M J Grusby, V K Clements
Journal of Immunology (Baltimore, Md. : 1950)
|
October 1, 1991
Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule
S Ostrand-Rosenberg, C A Roby, V K Clements
Tissue Antigens
|
May 1, 1996
Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells
S Ostrand-Rosenberg, S Baskar, N Patterson, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 54) with videos related to
Sort By:
Page
of 6
Developmental Biology
|
November 1, 1977
Human teratoma cells share antigens with mouse teratoma cells
S Ostrand-Rosenberg, M Edidin, M A Jewett
Journal of Immunology (Baltimore, Md. : 1950)
|
November 9, 2000
Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo
L Qi, J M Rojas, S Ostrand-Rosenberg
Journal of Immunology (Baltimore, Md. : 1950)
|
December 1, 1993
Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection
E Lamousé-Smith, V K Clements, S Ostrand-Rosenberg
Journal of Immunology (Baltimore, Md. : 1950)
|
June 1, 1983
Multiple splenic lymphoid cell subpopulations regulate H-2 antigen expression on teratocarcinoma cells in vivo
S Ostrand-Rosenberg, A L Cohn, J W Sandoz
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 4, 1998
Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo
T D Armstrong, V K Clements, S Ostrand-Rosenberg
Journal of Immunology (Baltimore, Md. : 1950)
|
April 29, 1998
MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes
T D Armstrong, V K Clements, S Ostrand-Rosenberg
Cancer Immunology, Immunotherapy : CII
|
April 29, 1998
Tumor antigen presentation: changing the rules
T D Armstrong, B A Pulaski, S Ostrand-Rosenberg
Journal of Immunology (Baltimore, Md. : 1950)
|
November 22, 2000
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
S Ostrand-Rosenberg, M J Grusby, V K Clements
Journal of Immunology (Baltimore, Md. : 1950)
|
October 1, 1991
Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule
S Ostrand-Rosenberg, C A Roby, V K Clements
Tissue Antigens
|
May 1, 1996
Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells
S Ostrand-Rosenberg, S Baskar, N Patterson, et al.
Page
of 6